Sam S. Chang MD, MBA, discusses intravesical mitomycin in low-grade intermediate-risk nonmuscle-invasive bladder cancer vs different treatment paths.
Sam Chang, MD, MBA
Advertisement
Sam Chang, MD, MBA, is the chief surgical officer at the Vanderbilt Ingram Cancer Center and the urologic oncology division chief.
Articles by Sam Chang, MD, MBA
Sam S. Chang MD, MBA, discusses the findings for mitomycin in for low-grade intermediate-risk nonmuscle-invasive bladder cancer.
Sam S. Chang, MD, MBA, discusses the methods and design of the QUILT 3032 study.
Sam S. Chang, MD, MBA, discusses the research of N-803 in combination with BCG in patients with BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Latest Updated Articles
Mitomycin Reverse Thermal Gel Shows Complete Response in LG-IR-NMIBCPublished: June 18th 2025 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
